The growing global demand for personalized medicine, coupled with the rising prevalence of cancer and other chronic diseases, is significantly fueling the expansion of the DNA methylation detection technology market. Advances in sequencing techniques, particularly those offering higher throughput and reduced cost, are also contributing to market de